Posts Tagged "initial vascular events"

ARRIVE: Aspirin does not reduce initial vascular events in low-to-moderate risk population

Posted on Dec 19, 2018 in Cardiovascular Health

Hear what Dr. Buttar and Robert Scott Bell have to say about this article on the August 27, 2018 Advanced Medicine Show (click link above to listen to the show) In a moderate-risk population with low event rates, aspirin did not significantly reduce initial vascular events, according to the ARRIVE study presented at the European Society of Cardiology Congress. Among 12,546 patients randomly assigned to receive enteric-coated aspirin (Bayer) 100 mg daily or placebo and followed for a median of 60 months, the primary efficacy endpoint of time to first occurrence of CV death, MI, unstable...

Read More